CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: Is there any benefit?

Indian Journal of Gastroenterology

Volumn 28, Issue 1, 2009, Pages 24-27

  Bedi, M M S ^a   Gandhi, M D ^a   Jacob, G ^a   Lekha, V ^a   Venugopal, A ^a   Ramesh, H ^a  

^a Lakeshore/PVS Memorial Hospitals   (India)

Author keywords

Carbohydrate antigen; Chronic pancreatitis; Inflammatory head masses

Indexed keywords

CA 19-9 ANTIGEN;

ARTICLE; BENIGN TUMOR; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CARCINOMA; ROC CURVE; SENSITIVITY AND SPECIFICITY;

CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 67649580268     PISSN: 02548860     EISSN: 02548860     Source Type: Journal    
DOI: 10.1007/s12664-009-0005-4     Document Type: Article

References (15)

1. Beger HG, Schlosser W, Poch B, Gansague F. Inflammatory mass in the head of the pancreas. In: Beger HG, Warshaw AL, Buchler MW, Carr-Locke DL, Neoptolemos JP, Russel C, editors. The Pancreas, vol 1. Oxford: Blackwell Science; 1998. p. 757-760
2. Ramesh H, Augustine P. Surgery in tropical pancreatitis: analysis of risk factors. Br J Surg 1992;79:544-549
3. Boll DT, Merkle EM. Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol 2003;13(Suppl. 5): M 42-49 (Pubitemid 38181034)
4. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-370 (Pubitemid 28230734)
5. Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas 1987;2:398-403.
6. Pulay I, Tihanyi TF, Flautner L. Pancreatic head mass: what can be done? Classification: the clinical point of view. JOP - J Pancreas 2000;1(3 Suppl.):85-90. (Pubitemid 38963896)
7. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg 2004;91:1410-1427 (Pubitemid 39518076)
8. Augustine P, Ramesh H. Is tropical pancreatitis premalignant? Am J Gastroenterol 1992;87:1005-1008
9. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000;89:83-88
10. Yiannakou JY, Newland P, Calder F, Kingsnorth AN, Rhodes JM. Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet 1997;349:389-392 (Pubitemid 27077667)
11. Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA 19-9 not associated with malignancy. South Med J 2006;99:306-308
12. Daram SR. CA 19-9: not a magic marker for pancreatic cancer. South Med J 2006;99:205.
13. Zweig MH, Campell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577 (Pubitemid 23118304)
14. Nouts A, Levy P, Voitot H, Bernades P. Diagnostic value of serum CA 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 1998;22:152-159
15. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993;328:1433-1437 (Pubitemid 23143844)